Table 1 Summary of the different experiments done in this study including the objectives of the experiments, treatments (with concentrations) and controls (with vehicles used to dissolve the agonists and antagonists) and the number of animals used in each group
Treatment/ Pretreatment | Objective | Control | Treatment Groups | ||
|---|---|---|---|---|---|
Vehicle | Concentration 1 | Concentration 2 | Concentration 3 | ||
PGE2 | To study the effect of treatment on citric acid-induced cough | 10% ethanol in ACSF (n = 12) | 0.3 mg/ml (n = 8) | 0.6 mg/ml (n = 12) | 1 mg/ml (n = 13) |
Sulprostone Non-selective EP1/EP3 agonist | To study the effect of treatment on citric acid-induced cough | 10% DMSO in ACSF (n = 9) | 0.1 mg/ml (n = 8) | 0.3 mg/ml (n = 7) | 1 mg/ml (n = 9) |
ONO-8130 EP1 receptor antagonist | To study the effect of pretreatment on sulprostone-enhanced citric acid-induced cough | 70% DMSO in ACSF  + sulprostone (1 mg/ml) (n = 10) | 1 mg/mL  + sulprostone (1 mg/ml) (n = 7) | 5 mg/mL  + sulprostone (1 mg/ml) (n = 6) | – |
L-798,106 EP3 receptor antagonist | To study the effect of pretreatment on sulprostone-enhanced citric acid-induced cough | 70% DMSO in ACSF + sulprostone (1 mg/ml) (n = 10) | 2.5 mg/mL  + sulprostone (1 mg/ml) (n = 7) | 5 mg/mL  + sulprostone (1 mg/ml) (n = 10) | – |
Butaprost EP2 receptor agonist | To study the effect of treatment on citric acid-induced cough | 10% DMSO in ACSF (n = 11) | 0.3 mg/ml (n = 8) | 1 mg/ml (n = 10) | – |
L-902,688 EP4 receptor agonist | To study the effect of treatment on citric acid-induced cough | 10% DMSO in ACSF (n = 7) | 0.3 mg/ml (n = 9) | 1 mg/ml (n = 8) | – |
JNJ-17203212 TRPV1 channel antagonist | To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough | 70% DMSO in ACSF +  PGE2 (1 mg/ml) (n = 10) | 0.4 mg/mL  + PGE2 (1 mg/ml) (n = 10) | 1.3 mg/mL  + PGE2 (1 mg/ml) (n = 9) | – |
HC-030031 TRPA1 channel antagonist | To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough | 5% DMSO in ACSF +  PGE2 (1 mg/ml) (n = 8) | 0.02 mg/mL +  PGE2 (1 mg/ml) (n = 7) | 0.05 mg/ml +  PGE2 (1 mg/ml) (n = 6) | – |
Combination JNJ-17203212 + HC-030031 | To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough | 70% DMSO in ACSF +  PGE2 (1 mg/ml) (n = 7) | 0.4 + 0.02 mg/mL + PGE2 (1 mg/ml) (n = 5) | 1.3 + 0.05 mg/mL + PGE2 (1 mg/ml) (n = 6) | – |
Tetrodotoxin (TTX) Tetrodotoxin-sensitive sodium channel antagonist | To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough | 99% ACSF + PGE2  (1 mg/ml)   (n = 7) | 0.015 µg/mL + PGE2 (1 mg/ml) (n = 7) | 0.1 µg/mL +  PGE2 (1 mg/ml) (n = 5) | – |
A-803467 NaV 1.8 channel antagonist | To study the effect of pretreatment on PGE2-enhanced citric acid-induced cough | 70% DMSO in ACSF +  PGE2 (1 mg/ml) (n = 6) | 5 mg/mL +  PGE2 (1 mg/ml) (n = 5) | 10 mg/mL +  PGE2 (1 mg/ml) (n = 5) | – |